Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

What Are the Predictive Factors for Preeclampsia in Oocyte Recipients? - PREROVE (PREROVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03668184
Recruitment Status : Recruiting
First Posted : September 12, 2018
Last Update Posted : December 18, 2018
Sponsor:
Information provided by (Responsible Party):
Rennes University Hospital

Brief Summary:
The main goal is to determine which risk factors develop preeclampsia in this specific group of oocyte recipients.

Condition or disease Intervention/treatment
Pregnancy Oocyte Donation Other: preeclampsia

Layout table for study information
Study Type : Observational
Estimated Enrollment : 157 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: What Are the Predictive Factors for Preeclampsia in Oocyte Recipients? - PREROVE
Actual Study Start Date : January 2, 2018
Estimated Primary Completion Date : July 1, 2019
Estimated Study Completion Date : October 1, 2019

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: preeclampsia
    occurrence of pre-eclampsia


Primary Outcome Measures :
  1. occurrence of pre-eclampsia [ Time Frame: through study completion, an average of 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Sampling Method:   Non-Probability Sample
Study Population
Patients with a pregnancy of more than 22 weeks of amenorrhea resulting from an oocyte donation.
Criteria

Inclusion Criteria:

  • All major patients with a pregnancy of more than 22 weeks of amenorrhea resulting from an oocyte donation in one of the study centers, having given birth between January 2010 and April 2017 and not opposed to participation in the study.

Exclusion Criteria:

  • all pregnancies resulting from an oocyte donation abroad, persons of legal age subject to legal protection (safeguard of justice, guardianship, tutorship) and persons deprived of their liberty.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03668184


Contacts
Layout table for location contacts
Contact: Kristell COAT 299282555 ext 33 kristell.coat@chu-rennes.fr
Contact: Direction de la Recherche et de l'Innovation 299282555 ext 33 drc@chu-rennes.fr

Locations
Layout table for location information
France
CHU de Rennes Recruiting
Rennes, France, 35033
Contact: Solène Duros, MD         
Principal Investigator: Solène DUROS, MD         
Clinique de la sagesse Recruiting
Rennes, France, 35043
Contact: Frédérique Jaffré, MD         
Principal Investigator: Frederic Jaffré, MD         
Sponsors and Collaborators
Rennes University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Solène DUROS, MD Rennes University Hospital

Layout table for additonal information
Responsible Party: Rennes University Hospital
ClinicalTrials.gov Identifier: NCT03668184     History of Changes
Other Study ID Numbers: 35RC17_3078_PREROVE
First Posted: September 12, 2018    Key Record Dates
Last Update Posted: December 18, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications